Yusuke Nakamura to Neoadjuvant Therapy
This is a "connection" page, showing publications Yusuke Nakamura has written about Neoadjuvant Therapy.
Connection Strength
0.482
-
Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.
Score: 0.174
-
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug; 49(2):471-8.
Score: 0.118
-
[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital]. Gan To Kagaku Ryoho. 2009 Aug; 36(8):1287-91.
Score: 0.074
-
Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2007 Jan; 98(1):113-7.
Score: 0.062
-
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005 Apr 01; 11(7):2625-36.
Score: 0.055